Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

Table 4 Secondary analysis: CD3, a pan T-cell marker

CD3+ density (mm²/mm²)	Rituximab Mean (95% CI)	Controls Mean (95% CI)	p
Tumor region	0.022 (0.012, 0.033)	0.042 (0.031, 0.053)	0.01
Non-neoplastic region	0.019 (0.011, 0.026)	0.021 (0.017, 0.025)	0.56
Within group difference
Tumor − non-neoplastic	0.004 (− 0.005, + 0.013)	0.021 (+ 0.011, + 0.031)	0.01

1. Density of tumor for subjects treated with Rituximab
2. Density of adjacent normal tissue for subjects treated with Rituximab
3. Use one sample t test to get the mean and 95% CI
4. p value is from two sample t-test
For two sample t-test, the Welch (or Satterthwaite) approximation to the degrees of freedom is used
Null hypothesis is no difference. Alternative hypothesis is true difference in means is greater than 0
5. (Tumor − Normal) is calculated by: column D − column E

ISSN: 1479-5876